Psilocybe cubensis a species of psychedelic mushroom whose principal active compounds are psilocybin and psilocin. Commonly called shrooms, magic mushrooms, golden halos, cubes, or gold caps, it belongs to the fungus family Hymenogastraceae and was previously known as Stropharia cubensis. It is the most well known psilocybin mushroom due to its wide distribution and ease of cultivation.
Discription: Buy psilocybe cubensis spores
The cap is 1.6–8 cm (0.6–3.1 in), conic to convex with a central papilla when young, becoming broadly convex to plane with age, retaining a slight umbo sometimes surrounded by a ring-shaped depression. The cap surface is smooth and sticky, sometimes with white universal veil remnants attached. The cap is brown becoming paler to almost white at the margin, and fades to more golden-brown or yellowish with age. When bruised, all parts of the mushroom stain blue. The narrow grey gills are adnate to adnexed, sometimes seceding attachment, and darken to purplish-black and somewhat mottled with age. The gill edges remain whitish. The hollow white stipe is 4–15 cm (2–6 in) high by 0.4–1.4 cm (0.2–0.6 in) thick, becoming yellowish in age. The well-developed veil leaves a persistent white membranous ring whose surface usually becomes the same colour as the gills because of falling spores. The mushroom has no odor, and tastes farinaceous. The psilocype cubensis spores are 11.5–17.3 x 8–11.5 µm, subellipsoid, basidia 4-spored but sometimes 2- or 3-, pleurocystidia and cheilocystidia present.
The related species Psilocybe subcubensis—found in tropical regions—is indistinguishable but has smaller spores.
Medical benefits of magic mushroom (psilocybe cubensis)
Research has shown psilocybin mushrooms to have potential to treat a range of psychiatric and behavioral disorders, although it’s yet to receive FDA approval for anything.
Its potential indications include depression, obsessive-compulsive disorder, quitting smoking, alcohol addiction, cocaine addiction, cluster headachesTrusted Source, and cancer-related or other end-of-life psychological distress.
High-profile initiatives have also popped up in recent months in Denver, Colorado, and Oregon to decriminalize psilocybin mushrooms.
Depression is among the most researched indications for psilocybin therapy. As Healthline previously reported last year, psilocybin therapy was given “breakthrough therapy” designation (a review fast track) by the FDA for the treatment of depression.
There are no reviews yet.